Laurus Labs Ltd. (LAURUSLABS) Share Price Hits Fresh 52-Week High
- July 29, 2026
- Posted by: Harsh Piplani
- Category: News
Laurus Labs Ltd. Share Price reached a fresh 52-week high of Rs 1,764.95, marking a 0.4% increase today. The company’s market capitalisation stands at Rs 92,612.28 crore.
Laurus Labs Ltd. Share Price has reached a fresh 52-week high of Rs 1,764.95, reflecting a 0.4% increase from the previous close of Rs 1,758. The stock opened at Rs 1,766.75 and reached a day high of Rs 1,769. With a market capitalisation of Rs 92,612.28 crore, Laurus Labs Ltd. is attracting significant attention in the healthcare sector. This milestone highlights the company’s current market momentum, although the specific catalyst for this rise is not detailed in the available data.
Laurus Labs Ltd. Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,764.95 |
| Previous Close | Rs 1,758 |
| Today's Change | +Rs 6.95 (+0.4%) |
| Day Open | Rs 1,766.75 |
| Fresh 52-Week High | Rs 1,769 |
| Day Low | Rs 1,755 |
| Current Volume | 9,377 |
| Turnover | Rs 1.65 crore |
| Market Capitalisation | Rs 92,612.28 crore |
Today, Laurus Labs Ltd. Share Price opened at Rs 1,766.75 and fluctuated between a low of Rs 1,755 and a high of Rs 1,769, eventually closing at Rs 1,764.95. This marks a 0.4% increase from the previous close of Rs 1,758. The stock’s turnover was Rs 1.65 crore, with a trading volume of 9,377 shares, indicating moderate market participation. The fresh 52-week high of Rs 1,769 underscores the stock’s upward trajectory, suggesting investor interest in the company’s prospects.
Laurus Labs Ltd. (LAURUSLABS) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 92,612.28 crore |
| P/E Ratio | 29.31x |
| P/B Ratio | 0.43x |
| ROE | -2.89% |
| ROCE | -0.26% |
Laurus Labs Ltd. was valued at a P/E ratio of 29.31x, a P/B ratio of 0.43x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.
Profitability and capital efficiency were represented by ROE of -2.89% and ROCE of -0.26%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Benchmark Scope | same sector |
| Company P/E Ratio | 29.31x |
| Benchmark Median P/E | 21.06x |
| Benchmark Average P/E | 68.59x |
| Benchmark P/E Range | 0x to 3,439.3x |
| Company P/B Ratio | 0.43x |
| Benchmark Median P/B | 1.88x |
| Company ROE | -2.89% |
| Benchmark Median ROE | 10.91% |
| Company ROCE | -0.26% |
| Benchmark Median ROCE | 13.2% |
| Company Market Capitalisation | Rs 92,612.28 crore |
| Benchmark Median Market Cap | Rs 140.64 crore |
Laurus Labs Ltd. (LAURUSLABS) is classified under sector: Healthcare. The numerical benchmark uses 198 same sector companies from the supplied master-data set.
Laurus Labs Ltd. (LAURUSLABS) has a P/E ratio of 29.31x, which is above the benchmark median of 21.06x, a difference of +39.17%. The benchmark contains 198 companies with P/E data, ranging from 0x to 3,439.3x. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Laurus Labs Ltd. (LAURUSLABS) has a ROE of -2.89%, which is below the benchmark median of 10.91%, a difference of -126.49%. Laurus Labs Ltd. (LAURUSLABS) has a ROCE of -0.26%, which is below the benchmark median of 13.2%, a difference of -101.97%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Dishman Carbogen Amcis Ltd. | DCAL | 2,921.65 | 29.31 | 0.43 | -2.89 | -0.26 |
| Kwality Pharmaceuticals Ltd. | KPL | 2,815.27 | 39.89 | 8.12 | 28.21 | 26.35 |
| Sai Parenteral's Ltd. | SAIPARENT | 2,476.69 | 169.37 | 3.13 | 13.9 | 12.97 |
| Beta Drugs Ltd. | BETA | 2,472.93 | 56.38 | 8.92 | 18.65 | 22.17 |
| Dr Agarwals Eye Hospital Ltd. | DRAGARWQ | 2,444.35 | 34.87 | 7.06 | -2.6 | 16.92 |
Laurus Labs Ltd. (LAURUSLABS) has a P/E ratio of 29.31x compared with the displayed peer median of 39.89x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of -2.89% compares with a peer median of 13.9% across the companies shown in the table. ROCE stood at -0.26% versus the displayed peer median of 16.92%, providing a capital-efficiency comparison. Laurus Labs Ltd. (LAURUSLABS) has a market capitalisation of Rs 92,612.28 crore. Among the 5 peers shown, 0 have a larger market capitalisation.
Why Investors Are Watching Laurus Labs Ltd.
- Fresh 52-week high at Rs 1,764.95, indicating strong price momentum.
- Attractive P/B ratio of 0.43 compared to sector median.
- Challenges in profitability with negative ROE and ROCE.
- Operates in the competitive healthcare sector with 198 peers.
About Laurus Labs Ltd.
Laurus Labs Ltd. is a prominent player in the healthcare sector, focusing on the production and development of pharmaceutical products. The company operates across various segments, including active pharmaceutical ingredients (APIs), formulations, and biotechnology. With a strong emphasis on research and development, Laurus Labs Ltd. aims to deliver high-quality and affordable healthcare solutions. Despite its current profitability challenges, the company remains a significant entity within the healthcare industry.
Track Laurus Labs Ltd. Share Price on Univest
Use Laurus Labs Ltd. (LAURUSLABS) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
Investors can track Laurus Labs Ltd. Share Price, technical indicators, fundamental ratios, and market insights on Univest. Stay updated with the latest 52-week levels and shareholding patterns for informed decision-making.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is Laurus Labs Ltd. Share Price today?
Ans. Laurus Labs Ltd. Share Price today is Rs 1,764.95, marking a 0.4% increase from the previous close of Rs 1,758. The stock reached a fresh 52-week high of Rs 1,769.
How does Laurus Labs Ltd.'s P/E ratio compare to the sector?
Ans. Laurus Labs Ltd.'s P/E ratio of 29.31 is above the sector median of 21.06 but below the sector average of 68.59, indicating a moderate valuation. The company trades at a P/E ratio of 29.31x.
What are Laurus Labs Ltd.'s profitability metrics?
Ans. Laurus Labs Ltd. reports a negative ROE of -2.89% and a negative ROCE of -0.26%, highlighting challenges in generating returns on equity and capital employed. ROE stands at -2.89%. ROCE stands at -0.26%.
How does Laurus Labs Ltd.'s P/B ratio compare to the sector?
Ans. Laurus Labs Ltd.'s P/B ratio of 0.43 is significantly lower than the sector median of 1.88, suggesting a potentially undervalued position. The company trades at a P/E ratio of 29.31x.
What is the market capitalisation of Laurus Labs Ltd.?
Ans. Laurus Labs Ltd. has a market capitalisation of Rs 92,612.28 crore, positioning it as a significant player in the healthcare sector. The company operates in the Healthcare sector. Its P/E ratio is 29.31x.
Who are Laurus Labs Ltd.'s peers?
Ans. Laurus Labs Ltd.'s peers include Dishman Carbogen Amcis Ltd., Kwality Pharmaceuticals Ltd., and Sai Parenteral's Ltd., among others in the healthcare sector. Comparable listed companies include Dishman Carbogen Amcis Ltd., Kwality Pharmaceuticals Ltd., Sai Parenteral's Ltd.
What sector does Laurus Labs Ltd. operate in?
Ans. Laurus Labs Ltd. operates in the healthcare sector, focusing on pharmaceutical products, including APIs, formulations, and biotechnology. The stock belongs to the Healthcare sector. 198 comparable companies were included in the benchmark.
How does Laurus Labs Ltd. compare to Kwality Pharmaceuticals Ltd.?
Ans. Laurus Labs Ltd. has a similar P/E ratio but lags in profitability metrics compared to Kwality Pharmaceuticals Ltd., which has higher ROE and ROCE. Comparable listed companies include Dishman Carbogen Amcis Ltd., Kwality Pharmaceuticals Ltd., Sai Parenteral's Ltd.
